Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (CRDF) has secured a new U.S. patent (No. 12,263,173) for its drug onvansertib in combination with bevacizumab (bev) for treating metastatic colorectal cancer (mCRC) patients. The patent, extending through 2043, covers treatment for all bev-naïve patients, including both RAS-mutated and RAS wild-type mCRC across all therapy lines.

This follows a previous patent for first-line treatment of bev-naïve patients with KRAS mutations. Onvansertib, a PLK1 inhibitor, is currently under evaluation in a Phase 2 randomized trial (CRDF-004) in combination with FOLFIRI/bev or FOLFOX/bev for first-line treatment of mCRC patients with RAS mutations. Initial trial data was released in December 2024, with additional results expected in first half of 2025.

Cardiff Oncology (CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has granted stock options as an employment inducement. The company issued non-qualified stock options for 35,040 shares to one new employee on April 14, 2025.

The options were granted under Nasdaq Listing Rule 5635(c)(4) with an exercise price of $2.79 per share, matching Cardiff's closing stock price on April 14, 2025. The vesting schedule spans 4 years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months, contingent on continued employment.

Cardiff Oncology (CRDF) has completed patient enrollment in its Phase 2 CRDF-004 trial, evaluating onvansertib combined with standard of care for first-line RAS-mutated metastatic colorectal cancer (mCRC) treatment. The trial, conducted across 41 U.S. clinical sites, involves patients with documented KRAS or NRAS mutations and unresectable disease.

The study design includes three arms where patients receive either 20mg onvansertib plus standard of care (FOLFIRI/FOLFOX with bevacizumab), 30mg onvansertib plus standard of care, or standard of care alone. The trial's primary endpoint is objective response rate (ORR), with secondary endpoints including progression-free survival, duration of response, and safety.

Initial results were released in December 2024, with additional clinical data expected in the first half of 2025.

Cardiff Oncology reported significant progress in its first-line RAS-mutated metastatic colorectal cancer (mCRC) clinical trial, with patients receiving 30mg onvansertib showing a 64% response rate compared to 33% in the control arm. The company successfully completed a $40 million oversubscribed offering and secured a new patent for onvansertib treatment in KRAS-mutated mCRC.

The company's financial position remains strong with $91.7 million in cash and equivalents as of December 31, 2024, providing runway into Q1 2027. Operating expenses increased to $49.3 million for 2024, up from $45.9 million in 2023, primarily due to clinical program costs and higher staffing expenses.

Additional clinical updates from the CRDF-004 trial are expected in H1 2025. The company also presented promising data at the San Antonio Breast Cancer Symposium and published clinical results in the Journal of Clinical Oncology.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech company focused on PLK1 inhibition for cancer therapies, has announced its participation in two upcoming investor conferences.

At the B. Riley Securities Precision Oncology & Radiopharma Conference on February 28, 2025, CEO Mark Erlander will participate in a panel discussion focusing on improving responses in colorectal cancer. This event will be held in New York City and is exclusively for in-person attendees.

Additionally, the company will present at the TD Cowen 45th Annual Health Care Conference in Boston on March 5, 2025, at 11:50 AM ET. This presentation will be accessible via webcast through Cardiff Oncology's website in the 'Events' section, with a replay available after the presentation.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotechnology company focused on PLK1 inhibition for cancer therapies, has announced it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025. The company will host a conference call and webcast at 4:30 p.m. ET/1:30 p.m. PT following market close.

Interested parties can access the webcast through the 'Investors' section of Cardiff Oncology's website. A replay of the call will be made available in the investor relations section afterward.

Cardiff Oncology (Nasdaq: CRDF) has announced the pricing of an oversubscribed underwritten registered direct offering of 15,384,619 common stock shares at $2.60 per share, aiming to raise approximately $40 million in gross proceeds. The offering attracted new mutual fund and healthcare dedicated investors, alongside existing investors' support.

The company plans to use the net proceeds to fund clinical costs for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) and for working capital. TD Cowen is leading the offering as book-runner, with William Blair, H.C. Wainwright & Co., and Craig-Hallum also participating in various roles. The offering is expected to close around December 11, 2024.

Cardiff Oncology (NASDAQ: CRDF) announced positive initial data from its Phase 2 CRDF-004 trial evaluating onvansertib combined with standard-of-care (SoC) in first-line RAS-mutated metastatic colorectal cancer patients. The trial demonstrated a 64% objective response rate (ORR) in the 30mg onvansertib dose arm versus 33% ORR in the control arm.

The 30mg dose showed superior results compared to the 20mg dose (64% vs. 50% ORR) with deeper tumor regression. The drug was well-tolerated at both doses. The randomized trial enrolled patients with KRAS or NRAS mutations, combining onvansertib with FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Additional clinical data is expected in 1H 2025.